The Luxembourg Institute of Health and Advanced Biological Laboratories develop joint diagnostic solutions to measure neutralizing antibodies against SARS-CoV-2 variants


The Luxembourg Institute of Health (LIH) and Advanced Biological Laboratories (ABL) are joining forces to predict immune protection against COVID-19 and support long-term vaccination strategies. To this end, the two laboratories have signed a license agreement and a collaboration agreement to provide two in vitro diagnostic solutions to measure neutralizing antibody levels. 

<< Back
11/01/2022 | Partenariat
  • logo abl

LIH has established a reference viral neutralization assay that measures the activity of neutralizing antibodies against the different SARS-CoV-2 Variants of Concerns.  This assay, realized in a BSL3 laboratory, is the reference assay to provide neutralization titers and predict immune protection against COVID-19 or disease severity. To rationalize long-term COVID vaccination strategies, LIH has also developed a more accessible surrogate variant neutralisation test, which measures neutralizing antibodies binding reflecting their neutralization activities.

This R&D collaboration proposes to establish a service-based product at LIH with the reference variant neutralization assay and to manufacture the surrogate variant neutralisation test for in vitro testing of the neutralization capacity of antibodies against different SARS-CoV-2 variants. 

Seeking an accurate diagnostic solution to predict immune protection

Immunity to SARS-CoV-2 induced by natural infection or vaccination reduces the risk of severe infection and affords a degree of protection against reinfection. “It is now clear that neutralizing serum antibodies contributes mainly to this protective role” says Dr Carole Devaux, head of the HIV-Clinical and Translational Research (HIV-CTR) group. “The effectiveness and the duration of protective immunity is challenged by the spread of highly transmissible viral variants that evade vaccine or monoclonal antibodies protection. It is now critical to propose standardized and sensitive tests to assess SARS-CoV-2 immunity and guide vaccination strategies at the personal level “

At LIH, Dr Danielle Perez Bercoff has set-up the reference viral assay used to predict vaccine efficacy in different clinical trials. However, there are few standardized and accurate serological in vitro tests, to date, able to predict the neutralizing activities of antibodies, and available for the different variants of concern. Dr Eveline Santos da Silva and Dr Danielle Perez Bercoff will be in charge at LIH to optimize the surrogate variant neutralization test for this purpose. The collaboration with ABL aims to make a Prove of Concept of the feasibility of such market and to manufacture the surrogate variant neutralisation test.

Pertinent innovation for the health sector 

Chalom Sayada, CEO and founder of ABL, adds: “We have been developing web and software-based diagnostic solutions for healthcare for more than 20 years now. Our focus has been on infectious diseases such as HIV, hepatitis and HPV, where we have built a global customer base. With COVID-19, we expanded our operations with the development and CE IVD registration of robust qPCR and Next Generation Sequencing assays for SARS-CoV-2 detection and variants identification, and now look forward to developing innovation for people with one of Luxembourg's leading healthcare players.”

Helping to quickly roll out efficient measures 

The relevance of the project is also central for LIH: “Such a partnership with ABL is extremely valuable for us. As part of our new strategy, we aim to have an impact that positively affects the lives of the patients and this partnership puts us in a position where we can effectively do that,” adds Ulf Nehrbass, CEO of LIH. 

A long time collaboration has been established between the research group HIV-CTR and ABL (SPREAD database, subtyping tool COMET) and new service agreements for SARS-CoV2 diagnostics were started in 2020 to support the R&D of ABL. Together with ABL, the research group speculated that a sensitive viral assay able to quantify the neutralizing titers against most VoCs and a surrogate variant neutralization test would be essential for the clinical management of patients in real-time to help to stratify the patients for the different vaccines, especially towards the outgrow of the VOCs. 

The collaboration aims to make a Prove of Concept of the feasibility of such market and to manufacture the surrogate variant neutralisation test.

Back to top  | << Back

Communiqués liés

13/01/2022 Partenariat

Anticiper menaces et opportunités grâce aux signaux faible...

Aujourd'hui, la fréquence des changements, et les impacts qui en découlent pou...

Mindforest Group
Kleos Patrol Mission Satellites 01 - Source Kleos Space

Kleos lance son nouveau groupe « Mission de Patrouille » e...

Kleos Space S.A. (ASX : KSS, Francfort : KS1), fournisseur de données de reconn...

Kleos Space S.A.
OCSiAl graphene nanotubes heating paints

Les nanotubes de graphène d’OCSiAl remplacent efficacemen...

L’utilisation de nanotubes de graphène augmente la productivité des peinture...


CACEIS accompagne ARDIAN et FiveT Hydrogen dans la création...

CACEIS, leader européen de l’Asset Servicing, a été choisi en tant que banq...

Dave Sparvell CEO Swissquote Bank Europe  01- Credit Swissquote Bank Europe

Keytrade Bank Luxembourg rejoint Swissquote Bank Europe pour...

Swissquote Bank Europe, la banque luxembourgeoise leader de l’investissement e...


B Medical Systems inaugurates its manufacturing facility in ...

B Medical Systems, a global leader in medical cold chain solutions, headquartere...

B Medical Systems

Il n'y a aucun résultat pour votre recherche

We use cookies to ensure the best experience on our website. By accepting you agree the use of cookies. OK Learn more